Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N‑[(6‑butoxynaphthalen‑2‑yl)sulfonyl]‑L‑glutamic acid is an experimental small molecule inhibitor of the bacterial enzyme MurD. By inhibiting MurD, which is involved in peptidoglycan biosynthesis, this compound disrupts bacterial cell wall synthesis and leads to bacterial cell death. It has not been approved for clinical use and remains at the experimental stage[1][3]. Its primary mechanism of action is antibacterial via inhibition of a key enzyme in cell wall formation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-[(6-butoxynaphthalen-2-yl)sulfonyl]-L-glutamic acid.